MET and papillary renal cell carcinoma: In order to uncover alternative therapeutic strategies for patients with papillary renal cell carcinoma, we tested the dose–response behaviors in two PRCC cell lines- one with a MET TK domain mutation (UOK345, H1112R) and a second with copy number gain of wild type MET (UOK342)- employing a MIPE library which was comprised of a panel of 1912 mechanistically annotated anti-cancer agents that are FDA approved or are currently being evaluated in clinical trials.